Effect of Oral Contraceptive Use in Relation to Fertile Years on the Risk of Endometriosis in Women with Primary Infertility: A Ten-Year Single-Centre Retrospective Analysis

Vesna Šalamun, Šalamun V, Gaetano Riemma, Klemenc A, Anja Klemenc, Antonio Simone Laganà, Pasquale De Franciscis, De Franciscis P, Martin Štimpfel, Sara Korošec, Helena Ban Frangež
Medicina (Kaunas, Lithuania) · 2024 · vol. 60(6) , pp. 959 · doi:10.3390/medicina60060959 · PMID:38929576 · W4399488413
Observational OA: gold CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study found that oral contraceptive use was not associated with an increased risk of endometriosis, but use for less than 25% of fertile age may offer protection against superficial implants.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Background and Objectives: Oral contraceptives (OCs) are usually used to treat endometriosis; however, the evidence is inconsistent about whether OC use in the past, when given to asymptomatic women, is protective against the development of future disease. We aimed to assess the relationship between the use of OCs and the likelihood of discovering endometriosis, considering the length of time under OCs during their fertile age. Materials and Methods: This was a monocentric retrospective cohort study in a tertiary-care University Hospital (Department of Human Reproduction, Division of Gynaecology and Obstetrics, University Medical Centre Ljubljana, Slovenia) carried out from January 2012 to December 2022. Reproductive-aged women scheduled for laparoscopic surgery for primary infertility and subsequent histopathological diagnosis of endometriosis were compared to women without an endometriosis diagnosis. They were classified based on the ratio of years of OC use to fertile years in four subgroups: never, 50. Results: In total, 1923 women (390 with and 1533 without endometriosis) were included. Previous OC use was higher in those with endometriosis than controls (72.31% vs. 58.64%; p = 0.001). Overall, previous OC usage was not related to histopathological diagnosis of endometriosis (aOR 1.06 [95% CI 0.87-1.29]). Women who used OCs for less than 25% of their fertile age had reduced risk of rASRM stage III endometriosis (aOR 0.50 [95% CI 0.26-0.95]; p = 0.036) or superficial implants (aOR 0.88 [95% CI 0.58-0.95]; p = 0.040). No significant results were retrieved for other rASRM stages. Using OCs for 50% of fertile age did not increase the risk of developing superficial endometriosis, endometriomas, or DIE. Conclusions: When OCs are used at least once, histological diagnoses of endometriosis are not increased. A protective effect of OCs when used for less than 25% of fertile age on superficial implants may be present. Prospective research is needed to corroborate the findings due to constraints related to the study's limitations.

My notes (saved in your browser only)

Outcome instruments

rASRM

Condition tags

endometriosisdie_deep_infiltratinginfertility

MeSH descriptors

Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (35)

Source provenance

europepmc
last seen: 2026-10-18T06:15:09.303036+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-18T06:13:12.368608+00:00
License: CC0 · commercial use OK